DECAU Denali Capital Acquisition Corp - Units (1 Ord Class A & 1 War)

About DECAU

Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate, SP-102, is a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe lumbosacral radicular pain. The company is headquartered in Palo Alto, CA.
50

Neutral Sentiment

How do you feel about DECAU?

Advertisement|Remove ads.